United Therapeutics Corp.

5 trials 1 recruiting Commercial sponsor

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

1 Recruiting

4 Completed trials

15 Countries active

2 Unique IMPs

100% Results reported

Phase III

100%

4 of 4 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Idiopathic pulmonary fibrosis 1 Pulmonary fibrosis 1

Top IMPs

TREPROSTINIL 3 RALINEPAG 2

All trials

5 total

A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects … Recruiting

2023-504904-26-00 Phase III 5 countries TREPROSTINIL
Extension Study of Inhaled Treprostinil in Subjects with Fibrotic Lung Disease Ended

2023-504471-25-00 Phase III 7 countries TREPROSTINIL
An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ralinepag in patients with pulmonary arterial hypertens… Ended

2023-509305-68-00 Phase III 15 countries RALINEPAG
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects … Ended

2024-514761-19-00 Phase III 7 countries TREPROSTINIL
A study evaluating the efficacy and safety of ralinepag in treatment of patients with pulmonary arterial hypertension. Ended

2023-509304-16-00 Phase III 15 countries RALINEPAG

Showing 1–5 of 5 trials

← All sponsors A–Z